Subscribe to Newsletter
Business & Profession Cornea / Ocular Surface, Business and Innovation, Other

H2-NO! A Water-Free Revolution in Eye Care

sponsored by Novaliq

Novaliq’s proprietary, water-free EyeSol® technology has been on the market in Europe, Australia and New Zealand -- first registered as ophthalmic medical devices in 2015. This year the company made significant progress with two accepted new drug applications which are currently in review by the U.S. Food and Drug Administration for the treatment of patients with dry eye disease. The company has bold plans to set a new gold standard in dry eye disease – but it doesn’t plan to stop there. 

EyeSol® Technology

Novaliq’s EyeSol® technology opens completely new opportunities to cure, relieve, and prevent diseases in a range of therapeutic areas. The proprietary water-free technology uses ultrapure semifluorinated alkanes (SFAs) that are physically, chemically, and physiologically inert, thus exhibiting excellent biocompatibility and an excellent safety profile. Overcoming the limitations of water or oil-based topical therapies, EyeSol® technology therefore leads to higher bioavailability of active pharmaceutical products all as it stabilizes sensitive active substances, including proteins or peptides. The absence of preservatives, surfactants, oils, osmolarity, and a pH also leads to increased tolerability and higher rates of patient satisfaction. 

Treating dry eye disease – taking two distinctive angles

Distinct from all anti-inflammatory and immunomodulatory agents, NOV03 (perfluorohexyloctane) was specifically designed to treat the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction (MGD). With its unique mode of action, NOV03 directly affects the lipid layer of the tear film preventing evaporation. 

CyclASol, a cyclosporine ophthalmic solution, was designed to better address the chronic inflammation causing keratitis and the progressive corneal surface damage. This first-of-its-kind anti-inflammatory eye drop solution should bring a more favorable efficacy/tolerability profile and better bioavailability compared to other marketed therapies for dry eye disease; given that patients with moderate to severe DED associated with keratitis benefit most from the rapid onset of action, this differentiation will be pivotal. 

If approved by the FDA, NOV03 and CyclASol® will all be game-changers in addressing important unmet needs in the treatment of dry eye disease that affects more than 16 million Americans (1). 

Water-free therapies as a novel drug category

Beyond dry eye treatments, the EyeSol® technology will help develop entirely new product families across multiple therapeutic areas. The company has multiple exciting ongoing research programs beyond DED and is planning to use small and large molecules to make the next big step into topical therapies for the treatment of retinal diseases. 

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. American Optometric Association, “New study focuses on scope of dry eye disease in U.S” (2017). Available at:
Related Case Studies
The Missing Piece of the Dry Eye Puzzle

| Contributed by Quidel

Uncovering Ocular Comorbidity

| Contributed by Quidel

Finding Ocular Surface Inflammation

| Contributed by Quidel

Related Product Profiles
Subspecialties Cornea / Ocular Surface
Tear Osmolarity – Empowering. Established. Essential.

| Contributed by TearLab

Subspecialties Cornea / Ocular Surface
Preservative-Free Cyclosporine 0.1% Ophthalmic Emulsion

| Contributed by ImprimisRx

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine



The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: